Infantile Hemangioma and Updated Recommended Treatment
Abstract
Infantile hemangioma is a benign vascular tumor that frequently occurs at pediatric age, normally at a rate of 2% to 12% in Caucasian newborn babies, particularly in females. The International Society for The Study of Vascular Anomalies has divided these anomalies into two categories: vascular tumors and vascular malformations, including infantile hemangioma among benign vascular tumors. Clinical evolution is characteristic, and consists of a proliferative phase and a spontaneous involution phase. Diagnosis is usually clinical, but sometimes other diagnostic procedures may eventually be necessary. The majority of infantile hemangioma has a favorable outcome and spontaneous resolution. However, in some cases there are local or systemic complications, with the need for additional therapeutic intervention in case of vital, functional or esthetic risks. Oral propranolol is the current treatment of choice for infantile hemangioma, being the only treatment internationally approved for this indication. It should be started as early as possible to maximize efficacy and avoid potential complications. Other therapeutic options can be considered as a second choice, such as oral, topical or intralesional corticosteroids, topical beta-blockers, pulsed-dye laser or surgery.
Downloads
References
Darrow DH, Greene AK, Mancini AJ, Nopper AJ. Diagnosis and Management of Infantile Hemangioma: Executive Summary. Pediatrics. 2015;136(4):786-791. doi:10.1542/peds.2015-2482
Léauté-Labrèze C, Harper JI, Hoeger PH. Infantile haemangioma. Lancet. 2017;6736(16):1-10. doi:10.1016/S0140-6736(16)00645-0
Passas MA, Teixeira M. Hemangioma da Infância. Nascer e Crescer. 2016;25(2):83-89. http://www.scielo.mec.pt/pdf/nas/v25n2/v25n2a05.pdf.
Paller AS, Mancini AJ. Vascular Disorders of Infancy and Childhood. In: Clinical Pediatric Dermatology. 5th ed. Elsevier; 2016:279-316.
Haggstrom A, Garzon M. Infantile Hemangiomas. In: Dermatology. 4th ed. Elsevier; 2017:1786-1804.
issva.org/classification [homepage na internet]. International Society for the Study of Vascular Anomalies © 2014. http://www.issva.org/UserFiles/file/Classifications-2014-Final.pdf. Accessed January 3, 2018.
Drolet BA, Frieden IJ. Characteristics of Infantile Hemangiomas as Clues to Pathogenesis. Arch Dermatol. 2010;146(11):1295-1299. doi:10.1001/archdermatol.2010.1295
Chen TS, Eichenfield LF, Friedlander SF. Infantile Hemangiomas: An Update on Pathogenesis and Therapy. Pediatrics. 2013;131(1):99-108. doi:10.1542/peds.2012-1128
North PE, Waner M, Mizeracki A, et al. A unique microvascular phenotype shared by juvenile hemangiomas and human placenta. Arch Dermatol. 2001;137(5):559-570. http://www.ncbi.nlm.nih.gov/pubmed/11346333.
Haggstrom AN, Lammer EJ, Schneider RA, Marcucio R, Frieden IJ. Patterns of infantile hemangiomas: new clues to hemangioma pathogenesis and embryonic facial development. Pediatrics. 2006;117(3):698-703. doi:10.1542/peds.2005-1092
Bauland CG, Lüning TH, Smit JM, Zeebregts CJ, Spauwen PHM. Untreated Hemangiomas: Growth Pattern and Residual Lesions. Plast Reconstr Surg. 2011;127(4):1643-1648. doi:10.1097/PRS.0b013e318208d2ac
Haggstrom AN, Beaumont JL, Lai J-S, et al. Measuring the Severity of Infantile Hemangiomas. Arch Dermatol. 2012;148(2):197-202. doi:10.1001/archdermatol.2011.926
Hoeger PH, Harper JI, Baselga E, et al. Treatment of infantile haemangiomas: recommendations of a European expert group. Eur J Pediatr. 2015;174(7):855-865. doi:10.1007/s00431-015-2570-0
Leaute-Labreze C, Boccara O, Degrugillier-Chopinet C, et al. Safety of Oral Propranolol for the Treatment of Infantile Hemangioma: A Systematic Review. Pediatrics. 2016;138(4):e20160353-e20160353. doi:10.1542/peds.2016-0353
Blei F, McElhinney DB, Guarini A, Presti S. Cardiac Screening in Infants with Infantile Hemangiomas before Propranolol Treatment. Pediatr Dermatol. 2014;31(4):465-470. doi:10.1111/pde.12344
Léauté-Labrèze C, Hoeger P, Mazereeuw-Hautier J, et al. A Randomized, Controlled Trial of Oral Propranolol in Infantile Hemangioma. N Engl J Med. 2015;372(8):735-746. doi:10.1056/NEJMoa1404710
Laranjo S, Costa G, Paramés F, et al. The role of propranolol in the treatment of infantile hemangioma. Rev Port Cardiol. 2014;33(5):289-295. doi:10.1016/j.repc.2013.10.018
Raphael MF, Breugem CC, Vlasveld FAE, et al. Is cardiovascular evaluation necessary prior to and during beta-blocker therapy for infantile hemangiomas? J Am Acad Dermatol. 2015;72(3):465-472. doi:10.1016/j.jaad.2014.12.019
Jacks SK, Kertesz NJ, Witman PM, Fernandez Faith E. Experience with Holter monitoring during propranolol therapy for infantile hemangiomas. J Am Acad Dermatol. 2015;73(2):255-257. doi:10.1016/j.jaad.2015.05.015
Hengst M, Oelert M, Hoeger PH. Blood Pressure Monitoring During the Induction and Maintenance Period of Propranolol Therapy for Complicated Infantile Hemangiomas: A Prospective Study of 109 Infants. Pediatr Dermatol. 2015;32(6):802-807. doi:10.1111/pde.12681
Petrovic J, Trifunovic B, Vukomanovic G, Topalovic M, Trajkovic G, Parezanović V. Oral propranolol for infantile hemangiomas: a prospective study on the role of 48-hour Holter monitoring in additional safety assessment. J Dermatolog Treat. 2017;28(6):554-558. doi:10.1080/09546634.2016.1277177
Ji Y, Chen S, Xiang B, Yang Y, Qiu L. Safety and tolerance of propranolol in neonates with severe infantile hemangiomas: a prospective study. Sci Rep. 2017;7(1):1503. doi:10.1038/s41598-017-01321-2
Carvalho S, Machado S, Selores M. Hemangioma infantil e propranolol oral: recomendações atuais TT - Infant hemangioma and oral propranolol current recommendations. Nascer e Crescer. 2016;25(3):154-158. http://www.scielo.mec.pt/pdf/nas/v25n3/v25n3a05.pdf.
Baselga Torres E, Bernabéu Wittel J, van Esso Arbolave DL, et al. Spanish consensus on infantile haemangioma. An Pediatría (English Ed. 2016;85(5):256-265. doi:10.1016/j.anpede.2015.10.017
ema.europa.eu [homepage da internet]. European Medicines Agency: EMA/111354/2014 - Resumo do Relatório Público Europeu de Avaliação (EPAR) de 2014 relativo ao Hemangiol. http://www.ema.europa.eu/docs/pt_PT/document_library/EPAR_-_Summary_for_the_public/human/002621/WC500166913.pdf. Accessed January 3, 2018.
Weibel L, Barysch MJ, Scheer HS, et al. Topical Timolol for Infantile Hemangiomas: Evidence for Efficacy and Degree of Systemic Absorption. Pediatr Dermatol. 2016;33(2):184-190. doi:10.1111/pde.12767
Puttgen K, Lucky A, Adams D, et al. Topical Timolol Maleate Treatment of Infantile Hemangiomas. Pediatrics. 2016;138(3):e20160355-e20160355. doi:10.1542/peds.2016-0355
Batta K, Goodyear HM, Moss C, Williams HC, Hiller L, Waters R. Randomised controlled study of early pulsed dye laser treatment of uncomplicated childhood haemangiomas: Results of a 1-year analysis. Lancet. 2002;360(9332):521-527. doi:10.1016/S0140-6736(02)09741-6
Greene AK. Management of hemangiomas and other vascular tumors. Clin Plast Surg. 2011;38(1):45-63. doi:10.1016/j.cps.2010.08.001
Greene AK, Mulliken JB. Vascular anomalies. In: Plastic Surgery: Volume 1: Principles. 4th ed. Elsevier; 2017:866-887.
Liang MG, Frieden IJ. Infantile and congenital hemangiomas. Semin Pediatr Surg. 2014;23(4):162-167. doi:10.1053/j.sempedsurg.2014.06.017
Dementieva N, Jones S. The treatment of problematic hemangiomas in children with propranolol and 940 nm diode laser. J Pediatr Surg. 2016;51(5):863-868. doi:10.1016/j.jpedsurg.2016.02.038
Coulie J, Coyette M, Moniotte S, Bataille A-C, Boon LM. Has Propranolol Eradicated the Need for Surgery in the Management of Infantile Hemangioma? Plast Reconstr Surg. 2015;136(4 Suppl):154. doi:10.1097/01.prs.0000472478.09496.0d
Greene AK. Infantile Hemangioma. In: Operative Management of Vascular Anomalies. 1st ed. Thieme; 2017:25-64. doi:10.1055/b-0037-145005
Couto RA, Maclellan RA, Zurakowski D, Greene AK. Infantile Hemangioma. Plast Reconstr Surg. 2012;130(3):619-624. doi:10.1097/PRS.0b013e31825dc129
Menapace D, Mitkov M, Towbin R, Hogeling M. The changing face of complicated infantile hemangioma treatment. Pediatr Radiol. 2016;46(11):1494-1506. doi:10.1007/s00247-016-3643-6
All articles in this journal are Open Access under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0).